Allogene Therapeutics (NASDAQ:ALLO) Coverage Initiated by Analysts at Citigroup
Citigroup started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research note released on Friday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $7.00 target price on the stock. ALLO has been the topic of a number of other research reports. JPMorgan Chase & Co. cut their […]